Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

IBO vs ENTX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

IBO Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 5–4 Matrix Metrics)

IBO Overall Winner 6-Pillar Tally: IBO 4 – 1 ENTX (1 Tie) Matrix Metrics: IBO 5 – 4 ENTX

As of Nov 16, 2026, Impact BioMedical, Inc. (IBO) is the stronger overall head-to-head candidate over Entera Bio Ltd. (ENTX) in the Tradestie Institutional Equity Comparison Engine, winning 5–4 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). IBO carries a Unified Composite Score of 36.8/100 (SELL) at $4.96 (N/M Forward P/E, -12621.0% operating margin), whereas ENTX carries 48.1/100 (HOLD) at $3.04 (N/M Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While ENTX currently prints a higher short-term Unified Composite Score (48.1/100 HOLD vs. IBO 36.8/100 SELL), IBO captures the overall institutional head-to-head verdict (5–4 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (-12621.0% vs. 0.0% operating margin) and revenue trajectory (+16.7% vs. -100.0% YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About IBO vs ENTX
IBO NYSE American Head-to-Head Winner
Impact BioMedical, Inc.
Pharmaceutical Preparations
$4.96
-3.5% 1D
Market Cap $41.2M
TTM Revenue $2.3M
Forward P/E N/M
Beta / 30D Vol -6.75β · 120% Vol
Unified Composite Score
36.8 / 100 SELL
Tech 15.0 Fund 32.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (71.0% over 20 days), RSI 62
RSI-14: 62.4 · SMA20: $4.12 · SMA50: $3.52
ENTX NASDAQ
Entera Bio Ltd. Ordinary Shares
Biological Products, (No Disgnostic Substances)
$3.04
-2.25% 1D
Market Cap $560.7M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.07β · 46% Vol
Unified Composite Score
48.1 / 100 HOLD
Tech 34.0 Fund 51.0 Flow 76.0 Mom 60.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (0.7% over 20 days), RSI 50
RSI-14: 50.4 · SMA20: $3.09 · SMA50: $2.90

6-Pillar Scorecard Institutional Category Breakdown (IBO 4 – 1 ENTX)

Columns: Metric · IBO · ENTX
1. Valuation Multiples IBO
Forward P/E N/M N/M
Trailing P/E 0.4x N/M
PEG Ratio N/M N/M
EV / Revenue 18.2x N/M
2. Growth & Scale IBO
Revenue Growth (YoY) +16.7% -100.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $2.3M N/A
Market Cap $41.2M $560.7M
3. Profitability & Quality IBO
Gross Margin N/A N/A
Operating Margin -12621.0% 0.0%
Net Profit Margin 4247.4% 0.0%
Return on Equity (ROE) 71.2% -138.9%
4. Balance Sheet & Cash Flow IBO
Cash Generation (TTM) -$99M -$16M
Cash Flow Margin N/A N/A
Net Cash / Leverage $1.18 Book/Sh · 71.2% ROE $265M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ENTX
Options Structure Phase UNCLASSIFIED CONSOLIDATION
Current IV / %ile N/A (N/A) 164.0% (47th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Markup
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat High-Margin Pricing Power Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: IBO (5) vs ENTX (4)
Institutional Metric IBO ENTX Criterion Row Edge
Market Capitalization
Scale
$41.2M $560.7M Larger Scale ENTX
Trailing P/E Ratio
Valuation
0.4x N/M Lower Multiple IBO
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+16.7% -100.0% Higher Growth IBO
Operating Margin (TTM)
Profitability
-12621.0% 0.0% Higher Margin ENTX
Net Profit Margin
Profitability
4247.4% 0.0% Higher Margin IBO
Return on Equity (ROE)
Capital Efficiency
71.2% -138.9% Higher ROE IBO
52-Week Range Position
Momentum
68% ($0–$7) 65% ($1–$4) Stronger Trend IBO
Beta / 30D Volatility
Risk Regime
-6.75β · 120% Vol 1.07β · 46% Vol Lower Realized Risk ENTX
Unified Institutional Score
Composite Signal
36.8 / 100 (SELL) 48.1 / 100 (HOLD) Higher Composite ENTX
Trailing 12M Revenue (USD)
Operating Scale
$2.3M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 18.2x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$99M ($1.18 Book/Sh · 71.2% ROE) -$16M ($265M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon IBO +71.64 pp
IBO: +85.07% · ENTX: +13.43%
3M Horizon IBO +950.13 pp
IBO: +955.32% · ENTX: +5.19%
6M Horizon IBO +674.27 pp
IBO: +821.42% · ENTX: +147.15%
1Y Horizon IBO +861.6 pp
IBO: +872.55% · ENTX: +10.95%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period IBO Revenue ENTX Revenue IBO Op. Margin ENTX Op. Margin Margin Leader
FY2020 N/A $0M N/A -3059.7% ENTX
FY2021 N/A $0M N/A -2139.6% ENTX
FY2022 $0M $0M -6808.0% -9714.2% IBO
FY2024 N/A $0M N/A -5295.6% ENTX
FY2025 $0M $0M -13381.2% -27450.0% IBO

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
IBO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact IBO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ENTX CONSOLIDATION
79d in phase · OBV NEUTRAL
Current IV 164.0%
IV Percentile 47th %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact ENTX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
IBO Moat Profile High-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $41.2M market capitalization and -12621.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ENTX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $560.7M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ IBO vs ENTX Key Questions & Quantitative Answers

As of Nov 16, 2026, Impact BioMedical, Inc. (IBO) is the stronger overall head-to-head candidate over Entera Bio Ltd. (ENTX) in the Tradestie Institutional Equity Comparison Engine, winning 5–4 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). IBO carries a Unified Composite Score of 36.8/100 (SELL) at $4.96 (N/M Forward P/E, -12621.0% operating margin), whereas ENTX carries 48.1/100 (HOLD) at $3.04 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While ENTX currently prints a higher short-term Unified Composite Score (48.1/100 HOLD vs. IBO 36.8/100 SELL), IBO captures the overall institutional head-to-head verdict (5–4 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (-12621.0% vs. 0.0% operating margin) and revenue trajectory (+16.7% vs. -100.0% YoY).

IBO leads the Growth & Scale pillar: IBO posts +16.7% YoY revenue growth and +0.0% YoY earnings growth on $2.3M TTM revenue (N/A gross margin, -12621.0% operating margin), compared with ENTX at -100.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). Across the 5-period historical trajectory (FY2020 to FY2025), IBO cumulative revenue shifted N/A while ENTX shifted N/A. In operating R&D and SG&A reinvestment, IBO deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ENTX.

IBO screens cheaper on headline valuation multiples. IBO trades at N/M Forward P/E, 0.4x Trailing P/E, N/M PEG, and 18.2x EV/Revenue (unreported FCF margin), whereas ENTX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against IBO (71.2% ROE) versus ENTX (-138.9% ROE) capital efficiency.

In options market volatility and institutional positioning, IBO carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-6.75β · 120% Vol realized risk). By comparison, ENTX carries 164.0% implied volatility (47th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.07β · 46% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.